Health & Pharmaceuticals
Washington / Six substances, zero FDA approvals and a comment window of about two weeks: the health secretary has used enforcement discretion to open a grey market to licensed pharmacies and physicians — over the objections of the FDA’s own staff, and before any final compounded-peptides rule exists
The RFK Jr peptides policy is now federal policy, at least for as long as nobody stops it. Health Secretary Robert F. Kennedy Jr. on Wednesday pushed forward an “enforcement discretion” policy, published in the Federal Register, that allows licensed pharmacies and physicians to compound six unapproved peptides without fear of reprisal from the Food and Drug Administration while regulators decide whether to permit them formally. None of the six has been approved by the FDA. The agency’s own staff recommended against allowing them. And the policy arrives not as a finished rule but as an interim promise: meet the conditions, and the FDA will look the other way.
Kennedy framed the move as a question of freedom and of safety at the same time. He has called himself a “big fan” of peptides and argued that Americans, blocked at home, were importing unsafe products from abroad instead. The policy, he said, “advances patient choice and freedom while appropriately protecting patient safety.” His department was more careful with its language. “The policy does not grant FDA approval or establish clinical safety and effectiveness,” an HHS spokesperson told CBS News — a sentence that deserves to be read twice, because it is the whole controversy in miniature. Access is being widened first. The evidence question is being left for later.
What are peptides, and why does everyone suddenly want them?
Peptides are short chains of amino acids — smaller than proteins, larger than the simple molecules of most pills, and central to how the body signals, repairs and regulates itself. Insulin is a peptide. So are the active ingredients behind the GLP-1 medicines that have reshaped diabetes and obesity care. Over the past year, a second peptide economy has boomed alongside the approved one: wellness influencers, anti-aging clinics and online sellers promoting injectable peptides for muscle recovery, tissue repair, sleep, pain and fat loss, long before regulators have judged whether the products work or what they do to the people taking them.
That boom created the policy problem Kennedy says he is solving. Demand did not wait for permission. It flowed into med spas, telehealth funnels and overseas websites selling vials labelled “for research use only” — a legal fig leaf that fooled no one and protected no one. HHS argues the new policy will discourage widespread use of those research-use-only products from foreign manufacturers and pull demand into licensed American pharmacies, where ingredients can at least be traced and tested. Critics answer that legitimising the demand is not the same as making the products safe, and that a federal green light, however hedged, will be heard by consumers as an endorsement the department insists it is not giving.
The six peptides, and what each is sold for
The policy covers six substances. Two are almost always discussed together; the other four reach into sleep, inflammation, metabolism and pain. None carries FDA approval for any use, and the purposes below are the uses for which they are marketed and sought after — not benefits the FDA has verified.
| Peptide | Marketed for | Notes |
|---|---|---|
| BPC-157 | Tissue repair and recovery | Half of the “Wolverine stack”; among the most requested compounds in wellness clinics |
| TB-500 | Tissue repair and recovery | Commonly taken together with BPC-157 as the “Wolverine stack” |
| Epitalon | Insomnia | Promoted in anti-aging and sleep circles |
| KPV | Wound healing and inflammatory conditions | Marketed for gut and skin inflammation as well as wounds |
| MOTS-c | Obesity and osteoporosis | A metabolic peptide pitched at weight and bone health |
| Semax | Migraines and chronic pain | Sold for pain and cognitive complaints |
BPC-157 and TB-500: the Wolverine stack at the centre of the fight
BPC-157 and TB-500 are the names most readers will recognise, because they are the pair the market already runs on. Taken together, they are nicknamed the “Wolverine stack” — after the comic-book mutant famous for healing almost instantly — and they are promoted for exactly that promise: faster repair of muscle, tendon and soft tissue. Gyms, recovery clinics and social media carried the stack into the mainstream long before Washington took a position on it. That is precisely why their inclusion matters most. The policy does not create demand for BPC-157 and TB-500; it relocates a large, existing, largely unregulated demand into pharmacies that operate under conditions the FDA can describe, even if the substances themselves remain unapproved.
The distinction between the six and one famous name that is not among them matters, because the grey market blurs it deliberately. Retatrutide — Eli Lilly’s investigational triple-G drug, which beat Ozempic in a head-to-head diabetes trial in results announced the same day — is not one of the six. It remains in clinical trials, unapproved and unreviewed by the FDA, and Wednesday’s policy does not change its status by one inch. Yet, as CBS News investigations have found, dozens of licensed clinics have openly advertised retatrutide anyway, and a lab test of a retatrutide sample bought at a Brooklyn bodega found it contained no peptide at all. A vial that contains nothing is the benign version of the grey market’s failure mode. A vial that contains the wrong thing, the wrong dose or a contaminant is the other one.
FDA peptide compounding rules: discretion with conditions attached
Enforcement discretion is a specific and limited tool, and its limits are the policy. The FDA is not approving the six peptides, not adding them to any approved list, and not reviewing compounded versions for safety, effectiveness or quality before they are marketed — compounded drugs, by definition, do not go through that review. What the department is promising is narrower: compounders who meet the policy’s requirements will not face enforcement action while the interim arrangement lasts. Those requirements cover, in the policy’s terms:
- Ingredients sourced from FDA-registered ingredient makers, with lab certificates for raw ingredients
- Standards for ingredient quality, manufacturing practice and quality testing
- Traceable ingredients from source to patient
- Safety reporting, including reports of serious side effects
- Proper labelling, and patient-specific prescriptions — no bulk production for anonymous stock
Read the list carefully and it describes a paper trail, not a proof. A certificate can establish what a powder was supposed to be; testing can establish what a batch contains; reporting can surface harm after it happens. None of it establishes, in advance, that BPC-157 heals tendons or that Semax is safe for a migraine patient taking three other medicines. That gap — between a documented product and a demonstrated medicine — is where the FDA’s own staff planted their flag, and lost.
The July fight: staff said no, the committee said yes
Kennedy’s public justification leans on process. He cited the FDA advisory committee’s recommendation in July, which voted to allow all six peptides. What that citation leaves out is the other half of the record: the FDA’s own staff had recommended against allowing the six. Advisory committees advise; agency scientists evaluate; and on this question the two pointed in opposite directions, with the secretary siding with the committee over his own agency’s reviewers.
The committee itself has drawn scrutiny. Several of its members had ties to businesses or clinics that sell peptides — the very trade that stood to gain from a yes vote. HHS has said all members cleared the department’s standard ethics checks, and there is no finding that any member acted improperly. But in a decision this consequential, the optics are part of the record: the recommendation Kennedy relied on came from a panel that included people connected to the industry being regulated, against the advice of staff with no such stake. Opponents have not forgotten it, and neither, in the comment period now opening, will they let anyone else forget it.
Are compounded peptides safe? The critics’ case
The sharpest response came from Public Citizen. Dr. Robert Steinbrook, director of its Health Research Group, said Kennedy had acted “recklessly and unilaterally,” arguing that the decision undermines the FDA and threatens public health. His case is the traditional one, and it has not weakened with repetition: the risks of unapproved compounded products include contamination, impurities and side effects nobody has systematically measured, and the remedy is the standard one — every one of these peptides should go through the ordinary FDA approval process, where claims are tested before they are sold. Steinbrook advised clinicians to warn their patients explicitly about contamination risk.
The pharmacy establishment, notably, did not line up behind a policy written for pharmacies. The Partnership for Safe Medicines, a coalition of pharmacy and pharmacist organisations, filed a citizen petition last week urging the FDA to ignore its advisory committee’s recommendation. Its executive director, Shabbir Safda, said the decision leaves Americans in a grey area on safety — a phrase that captures the strangeness of the moment. The products will be legal to compound, illegal to call approved, available in a pharmacy and unendorsed by the regulator, all at once. Nor does Washington’s word settle the map. Oversight of compounding is shared between the FDA and state pharmacy boards, and states may not follow the federal move, Jeff Cohen of the American Peptide Association noted — which means a prescription that is unremarkable in one state may be unavailable, or contested, in the next. It is worth setting this decision beside the week’s other big federal health document, the CDC’s first drug-resistant germs threat report since 2019: one arm of the health department cataloguing, in painstaking detail, what happens when medicines are used faster than the evidence and oversight around them, while another widens access to medicines that have cleared neither bar.
Why this matters
Approval is being replaced by permission, and permission is a weaker thing. The American drug system, for all its cost and slowness, rests on one bargain: a company proves a product safe and effective, and in return may sell it. Wednesday’s policy builds a side door next to that bargain — not for a rare disease with no alternative, but for six consumer-demanded substances with active commercial markets. Once a side door exists and a market organises itself behind it, closing it becomes a political act rather than a scientific one. That, more than any single peptide, is the precedent being set.
Count the numbers, because they do not sit comfortably together. Six substances. Zero FDA approvals. A public comment window of roughly two weeks, opening Friday and closing November 13. An industry analysts estimate could quickly become a $2 billion to $3 billion market once legitimised. And no final rule: the FDA has not yet even proposed the compounded-peptides rule this interim policy is meant to precede. A multi-billion-dollar market is therefore being invited to form first, and to be regulated afterwards — the reverse of the order the approval system was built to enforce.
The capacity question is real, whichever side is right. NPR reported that HHS will let small compounding pharmacies make the six — and that this may not be enough to meet demand. Compounding is, by law and by design, small-batch and patient-specific. If demand arrives at telehealth scale and the licensed channel cannot absorb it, the overflow does not vanish; it returns to the bodegas, websites and research-use-only sellers the policy was meant to displace, now with a federal decision to point to as cover.
Who gains: patients, clinics and a $2 billion to $3 billion market
The supporters are not shy, and their strongest argument is the one about the status quo. Lee Rosebush, chair of the American Academy of Peptide Medicine, called the decision a “landmark regulatory milestone” that clears a path for clinical innovation and expanded access. Patients who believe these compounds helped them — and there are many, particularly around injury recovery — gain a legal, traceable supply and a prescriber who can discuss their use openly instead of pretending it is not happening. Clinics gain products they can offer without looking over their shoulders. Compounding pharmacies gain a market. And telehealth companies, Hims & Hers Health among them, have been preparing peptide offerings that can now be built in the open. HHS, for its part, presents the policy as harm reduction with an exit: an interim arrangement it says it may reconsider if safety signals or quality problems emerge.
That exit clause deserves the same scrutiny as the entrance. A reconsideration triggered by “safety signals” in a system with no pre-market testing depends entirely on harms being noticed, reported and attributed — in a market where patients may be taking several compounds at once, bought from several sources, for conditions that fluctuate on their own. The safety-reporting requirement is therefore not a bureaucratic footnote. It is the only early-warning system this policy has.
What happens next
The immediate calendar is short. The draft policy opens for public comment on Friday and the window closes on November 13 — about two weeks for patients, clinics, pharmacists, insurers and critics to put their cases on the record. The policy itself stays in place until the FDA finalises a compounded-peptides rule, and the agency has not yet proposed one, so “interim” could describe months or considerably longer. Expect the states to move on their own clocks: pharmacy boards that align with Washington, boards that wait, and possibly boards that push back, producing the patchwork Cohen predicted. Expect, too, the argument to migrate. A citizen petition is already on file; decisions of this shape tend to attract congressional attention and, eventually, lawyers. And watch the one trigger HHS itself named. The first credible safety signal — a contaminated batch, a cluster of serious side effects, a product that is not what its label claims — will test whether an interim policy built on discretion can be tightened as fast as it was loosened. Until then, six unapproved peptides are, as of Wednesday, open for business in America’s pharmacies: legally compounded, officially unapproved, and carrying a question the FDA usually insists on answering first.
Sources
- Reuters, October 28, 2026, by Sneha S K: reporting on Kennedy’s enforcement discretion policy for six unapproved peptides — the Federal Register publication, the FDA staff recommendation against, the July advisory committee vote and the market estimates. reuters.com
- CBS News, October 2026: coverage of the policy and its conditions, including the HHS spokesperson’s statement that the policy does not grant FDA approval or establish safety and effectiveness, and CBS investigations into grey-market retatrutide, including the Brooklyn bodega sample that contained no peptide. cbsnews.com
- NPR, October 2026: reporting that HHS will let small compounding pharmacies make the six peptides, and that capacity may not meet demand. npr.org
- US Department of Health and Human Services / Federal Register, October 2026: the enforcement discretion policy for compounded peptides — the six substances, the conditions for compounders and the public comment period running through November 13. federalregister.gov · hhs.gov
Note: none of the six peptides covered by the policy — BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax — is FDA-approved, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before marketing. Uses listed in this article are the uses for which the substances are marketed, not verified benefits. Retatrutide is not one of the six and remains an investigational drug in clinical trials.